阅读说明：本技术 一种新型酪氨酸激酶抑制剂-安罗替尼在骨肉瘤和软骨肉瘤的应用 (Application of novel tyrosine kinase inhibitor-Arotinib in osteosarcoma and chondrosarcoma ) 是由 华莹奇 王刚阳 蔡郑东 王卓莹 张涛 汪红胜 孙梦熊 王训强 湛筱乐 杨朝强 屠 于 2019-01-16 设计创作，主要内容包括：本发明涉及安罗替尼的新用途,属于药物技术领域,即安罗替尼抑制骨肉瘤和软骨肉瘤生长和转移。其优点表现在：本发明首次发现安罗替尼可抑制骨肉瘤和软骨肉瘤生长和转移。安罗替尼能够明显抑制骨肉瘤细胞系143B、U2OS、MG63和SJSA生长,诱导其周期阻滞,同时也能够抑制骨肉瘤细胞系迁移和侵袭。本发明首次发现安罗替尼能够增强化疗药物顺铂对骨肉瘤细胞的杀伤作用。(The invention relates to a new application of nilotinib, belonging to the technical field of medicaments, namely the nilotinib is used for inhibiting the growth and transfer of osteosarcoma and chondrosarcoma. Its advantages are: the invention discovers for the first time that the nilotinib can inhibit the growth and metastasis of osteosarcoma and chondrosarcoma. The erlotinib can obviously inhibit the growth of osteosarcoma cell lines 143B, U2OS, MG63 and SJSA, induce cycle arrest of the osteosarcoma cell lines, and simultaneously can inhibit migration and invasion of the osteosarcoma cell lines. The invention discovers for the first time that the Arotinib can enhance the killing effect of the chemotherapeutic drug cisplatin on osteosarcoma cells.)

Use of nilotinib and pharmaceutically acceptable salts thereof in the preparation of a medicament for inhibiting osteosarcoma and/or chondrosarcoma.

Use of nilotinib and its pharmaceutically acceptable salts as a potentiator of cisplatin in the inhibition of osteosarcoma and/or chondrosarcoma.

Use according to claim 1 or 2, wherein the pharmaceutically acceptable salt of angutinib is angutinib hydrochloride.

The use of claim 1 or 2, wherein the medicament inhibits the growth and/or metastasis of osteosarcoma and/or chondrosarcoma.

The use of claim 4, wherein the osteosarcoma and/or chondrosarcoma metastasis is metastatic and/or invasive.

The use of claim 1 or 2, wherein the osteosarcoma is a primary osteosarcoma and/or a secondary osteosarcoma.

The use according to claim 1 or 2, wherein the osteosarcoma is an osteogenic osteosarcoma and/or a osteolytic osteosarcoma.

The use according to claim 1 or 2, wherein the osteosarcoma is an osteoblastic osteosarcoma, a chondroblastic osteosarcoma and/or a fibroblast osteosarcoma.

The use of claim 1 or 2, wherein the chondrosarcoma is a dedifferentiated chondrosarcoma and/or a hyperdifferentiated chondrosarcoma.

The use of claim 1, wherein said medicament comprises a therapeutically effective amount of aritinib and a pharmaceutically acceptable carrier.